{"id":24189,"date":"2023-07-04T04:13:00","date_gmt":"2023-07-03T20:13:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=24189"},"modified":"2023-07-04T05:47:35","modified_gmt":"2023-07-03T21:47:35","slug":"bmj%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e6%84%9f%e6%9f%932%e5%b9%b4%e5%90%8e%e7%97%85%e6%83%85%e6%81%a2%e5%a4%8d%e4%b8%8e%e9%81%97%e7%95%99%e7%97%87","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=24189","title":{"rendered":"[BMJ\u53d1\u8868\u8bba\u6587]\uff1a\u65b0\u51a0\u75c5\u6bd2\u611f\u67d32\u5e74\u540e\u75c5\u60c5\u6062\u590d\u4e0e\u9057\u7559\u75c7\u72b6"},"content":{"rendered":"\n

Research<\/strong><\/p>\n\n\n\n

Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study<\/h1>\n\n\n\n

Tala Ballouz, Dominik Menges, Alexia Anagnostopoulos, et al<\/h3>\n\n\n\n

BMJ<\/em>\u00a02023;\u00a0381\u00a0doi:\u00a0https:\/\/doi.org\/10.1136\/bmj-2022-074425<\/a>\u00a0(Published 31 May 2023)Cite this as:\u00a0BMJ<\/em>\u00a02023;381:e074425<\/h3>\n\n\n\n

Abstract<\/h2>\n\n\n\n

Objective<\/strong> To evaluate longer term symptoms and health outcomes associated with post-covid-19 condition within a cohort of individuals with a SARS-CoV-2 infection.<\/p>\n\n\n\n

Design<\/strong> Population based, longitudinal cohort.<\/p>\n\n\n\n

Setting<\/strong> General population of canton of Zurich, Switzerland.<\/p>\n\n\n\n

Participants<\/strong> 1106 adults with a confirmed SARS-CoV-2 infection who were not vaccinated before infection and 628 adults who did not have an infection.<\/p>\n\n\n\n

Main outcome measures<\/strong> Trajectories of self-reported health status and covid-19 related symptoms between months six, 12, 18, and 24 after infection and excess risk of symptoms at six months after infection compared with individuals who had no infection.<\/p>\n\n\n\n

Results<\/strong>\u00a022.9% (95% confidence interval 20.4% to 25.6%) of individuals infected with SARS-CoV-2 did not fully recover by six months. The proportion of individuals who had an infection who reported not having recovered decreased to 18.5% (16.2% to 21.1%) at 12 months and 17.2% (14.0% to 20.8%) at 24 months after infection. When assessing changes in self-reported health status, most participants had continued recovery (68.4% (63.8% to 72.6%)) or had an overall improvement (13.5% (10.6% to 17.2%)) over time. Yet, 5.2% (3.5% to 7.7%) had a worsening in health status and 4.4% (2.9% to 6.7%) had alternating periods of recovery and health impairment. The point prevalence and severity of covid-19 related symptoms also decreased over time, with 18.1% (14.8% to 21.9%) reporting symptoms at 24 months. 8.9% (6.5% to 11.2%) of participants reported symptoms at all four follow-up time points, while in 12.5% (9.8% to 15.9%) symptoms were alternatingly absent and present. Symptom prevalence was higher among individuals who were infected compared with those who were not at six months (adjusted risk difference 17.0% (11.5% to 22.4%)). Excess risk (adjusted risk difference) for individual symptoms among those infected ranged from 2% to 10%, with the highest excess risks observed for altered taste or smell (9.8% (7.7% to 11.8%)), post-exertional malaise (9.4% (6.1% to 12.7%)), fatigue (5.4% (1.2% to 9.5%)), dyspnoea (7.8% (5.2% to 10.4%)), and reduced concentration (8.3% (6.0% to 10.7%)) and memory (5.7% (3.5% to 7.9%)).<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions<\/strong> Up to 18% of individuals who were not vaccinated before infection had post-covid-19 condition up to two years after infection, with evidence of excess symptom risk compared with controls. Effective interventions are needed to reduce the burden of post-covid-19 condition. Use of multiple outcome measures and consideration of the expected rates of recovery and heterogeneity in symptom trajectories are important in the design and interpretation of clinical trials.<\/p>\n\n\n\n

Study registration<\/strong> Current Controlled Trials ISRCTN14990068<\/a><\/p>\n\n\n\n

Current Controlled Trials ISRCTN18181860<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Research Recovery and symptom trajectories up to two ye […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24189"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24189"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24189\/revisions"}],"predecessor-version":[{"id":24190,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24189\/revisions\/24190"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}